Why peptide 'stacks' fail evidence standards, and why this site publishes no doses

The "stack" is the unit of sale in the peptide market: two or three vials, a protocol, a timeline, a price. It is also the point at which evidence stops being possible. This page explains why, using the two most common stacks, and then explains the editorial rule that follows from it.

The GH stack: CJC-1295 with ipamorelin

The pitch is mechanistic and plausible: a GHRH analogue raises the amplitude of growth hormone pulses, a secretagogue adds a pulse of its own, and together they produce more GH than either alone. In healthy volunteers, each half has been shown to raise GH in a short study (CJC-1295, PubMed 16352683; ipamorelin, PubMed 10496658).

Now count what is missing. No trial of the combination in humans. No trial of either component for body composition, sleep, recovery or ageing. One clinical-outcome trial of ipamorelin, negative. FDA safety concerns published for both, including, for CJC-1295, increased heart rate and systemic vasodilatory reactions. A GHRH analogue that binds albumin for a week, combined with a second GH stimulus, in a population that has never been studied, at doses from a forum.

Compare the one GHRH analogue with a label. Tesamorelin raises GH and IGF-1 in the same way, and its label warns of neoplasm risk, fluid retention, glucose intolerance and 50% antibody formation, because a regulator made someone measure those things in 806 people. Nobody has measured them for the stack. The absence of a warning is not the absence of a risk; it is the absence of a study.

The healing stack: BPC-157 with TB-500

Here the components have no controlled human trial at all. BPC-157 has three uncontrolled reports from one clinic. TB-500 has none; FDA states it has identified no human exposure data. The one publication that combined them (PubMed 34324435) was a retrospective chart review of knee-pain patients, some given BPC-157 alone and some with TB-4, with no control group. Both substances were placed in Category 2 on September 29, 2023 and were discussed by the compounding advisory committee on July 23, 2026.

A 2026 review in Sports Medicine (PubMed 41966639) of approved and unapproved peptides for musculoskeletal injury reaches the conclusion the numbers force: the unapproved compounds are being used ahead of any human efficacy or safety evidence.

Why combinations cannot be graded

• Attribution. If a two-component stack seems to help, nothing tells you which component did it, whether the other added anything, or whether it was time and expectation. A stack is an uncontrolled experiment by construction.
• Dose. Trial doses, where they exist, were single-agent. There is no human data on what either component does in the presence of the other.
• Immunogenicity. Each peptide is a separate antigen with separate impurities. FDA's concern about aggregation and peptide-related impurities applies to each vial, and to whatever happens when two are drawn into one syringe.
• Source. Stack components are almost always research-use-only chemicals, with no requirement for identity, sterility or potency testing for human use. The compounding site explains that label.

A grade describes evidence for a substance and a use. A stack has neither a single substance nor a tested use, so it has no grade. The best that can be said is that it is a combination of C's and D's.

The editorial rule that follows

This site publishes no dose for any substance without an FDA label, no reconstitution or injection instructions except by reference to an FDA label for an approved product, and no links to sellers.

The reasons are stacked too. There is no defensible source for a dose of a research peptide. Publishing one would lend forum numbers an authority they have not earned. And FDA treats the combination of dosing content, reconstitution instructions and access to product as evidence that a substance is intended for use as a drug in humans, which for a Category 2 peptide is exactly the claim the evidence does not support. A reference site that provided those three things would be making that claim while pretending not to.

If a licensed prescriber has prescribed a medication and a licensed pharmacy has dispensed it with instructions, the arithmetic for a vial belongs on the label and, if you want to check it, in the reconstitution tool on our calculator site, which pre-fills nothing. The storage-life countdown here counts down to the beyond-use date the pharmacy printed. Neither tool has any opinion about a research chemical, and that is deliberate.